Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank at the Jefferies Virtual Global Healthcare Conference  (Replay)
    Tuesday, June 02, 2020 4:00 pm EDT
Toggle Summary Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015
MILFORD, Mass., April 13, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced two poster presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B Virus
Toggle Summary Spring Bank Pharmaceuticals to Present Novel Approach to Hepatitis B Treatment at the 2015 AASLD and Industry Colloquium
MILFORD, Mass. – March 12, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of hepatitis B and other viral infections, today announced that Radhakrishnan P. (Kris) Iyer, Ph.D., Chief Scientific Officer of Spring
Toggle Summary Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance
MILFORD, Mass., February 26, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of virus infections, today announced that Jonathan P. Freve, CPA, has been appointed Vice President of Finance, a newly created role. Mr.
Toggle Summary Spring Bank Pharmaceuticals Completes $22 Million Financing – Proceeds to Support Phase II Clinical Development of SB 9200 Against Hepatitis B
MILFORD, Mass., February 26, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of Hepatitis B virus (HBV) and other viral infections, today announced the closing of a $22 million financing.
Toggle Summary Spring Bank Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
MILFORD, Mass., Jan. 28, 2015 — Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced that Douglas J. Jensen, President and CEO, will present at the 17(th) annual BIO CEO & Investor
Toggle Summary Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens
MILFORD, Mass. – September 18, 2014 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the
Toggle Summary Spring Bank Pharmaceuticals Presents at the Nucleic Acid Summit 2014
MILFORD, Mass. – June 23, 2014   Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced two presentations at the Nucleic Acid
Toggle Summary Spring Bank Pharmaceuticals Announces Oral and Poster Presentations at the 27th International Conference on Antiviral Research
MILFORD, Mass. – May 12, 2014 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead
Toggle Summary Spring Bank Pharmaceuticals SB9200 Listed as Scientific Success Story
NIH – National Institute of Allergy and Infectious Diseases lists Spring Bank Pharmaceuticals SB9200 as one of their scientific success stories. To read full story click here
Toggle Summary Veteran Biotech Executive David Arkowitz Joins Spring Bank Pharmaceuticals’ Board of Directors
Seasoned Executive Brings Extensive Track Record of Business and Financial Experience to Clinical Stage Company MILFORD, Mass., Jan. 28, 2014 /PRNewswire/ — Spring Bank Pharmaceuticals today announced that David Arkowitz has been appointed to its Board of Directors.  Mr.